Journal of International Psychiatry

[Abstract] Objective: To explore the value, efficacy, and safety of paroxetine hydrochloride tablets in the treatment of patients with Parkinsons disease and depression. Methods: Researchers randomly selected 96 patients with Parkinsons disease and depression diagnosed by doctors in our hospital during the period from January 2021 to December 2022. After admission, 48 patients in each group were divided into single and double numbers. Patients in the control group were treated with regular treatment, while patients in the observation group were treated with paroxetine hydrochloride tablets on the basis of the control group. The clinical efficacy, incidence of adverse reactions, and psychological status of anxiety and depression, cognitive function, and improved Webster symptom scores were evaluated before and after treatment. Results: After treatment with paroxetine hydrochloride tablets, the anxiety and depression scores of 48 patients in the observation group were significantly lower than those in the control group (P<0.05); The clinical efficacy recorded in the observation group was significantly higher than that in the control group (P<0.05); The incidence of adverse reactions recorded in the observation group was lower than that in the control group (P<0.05); The cognitive function score in the observation group was higher than that in the control group (P<0.05); The evaluation of the observation group showed that the modified Webster symptom score was lower than that of the control group (P<0.05). Conclusion: During the treatment of patients with Parkinsons disease and depression, selecting paroxetine hydrochloride tablets can not only improve their anxiety and depression symptoms, but also ensure the effectiveness and safety of treatment, and alleviate the impact of the disease on cognitive function of patients.

Keywords: paroxetine hydrochloride tablets; Parkinsons disease; Depression; Clinical effects; Incidence rate of adverse reactions; cognitive function